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Organophosphorus inhibitors (OFi) of acetylcholinesterase (AChE) represent an 
extremely toxic group. Members of this group can be used as a military weapon or misused 
for terroristic purposes. We can also find their utilization in agriculture as pesticides and in 
the industry (plasticizers etc.). These compounds inhibit AChE at the serine hydroxyl group at 
its active site. The inhibited enzyme cannot fulfill its physiological role in the organism – i.e. 
splitting the neuromediator acetylcholine ACh at the synaptic clefts. Consequently, ACh 
accumulates in the cholinergic synaptic junctions. The poisoning manifests as a cholinergic 
syndrome. In cases of insufficient treatment, death is caused by paralysis of the respiratory 
muscles and of the respiratory center in the brain  [1, 2]. 
Symptomatical treatment of the OF poisoning is provided by two main groups of drugs. 
(1) Anticholinergics, like atropine, are able to antagonize the effects of excessive ACh by a 
blockade of muscarinic receptors. (2) Reactivators of AChE - oximes - are able to restore the 
physiological function of inhibited AChE. In addition, diazepam or other benzodiazepines can 
be used as anticonvulsants. Anticholinergics and reactivators are usually administered 
together because of their synergistic effect [3, 4]. Today, HI-6 and obidoxime are the most 
commonly used oxime reactivators in the treatment of organophosphorus poisoning. 
However, the reactivators differ in their efficacy against individual nerve agents and no 
universal antidote has been developed yet. Moreover, the problem of “aging” is also an 
important issue. Owing to this fact, new, versatile AChE reactivators, are thus required, or 
alternative treatment approaches may be introduced. 
Such an alternative approach presumes other oximes´ mechanism of action, not related to 
the reactivation [5]. Oximes have been reported to act at several levels of the cholinergic 
transmission including synthesis, release, inactivation and re-uptake of the transmitter, but the 
interaction with muscarinic and nicotinic receptors, has been put forward as the most 
plausible alternative of mechanism of action.  
The aim of this dissertation project deals with the interaction of oxime reactivators with 
muscarinic and nicotinic receptors. The experimental part has been based on the review of 
available literature [6] and include both in-vitro and in-vivo testing in order to investigate their 
antimuscarinic and antinicotinic properties. The differences in efficacy and anticholinergic 
potency of the individual reactivators, and further, the correlation between in-vitro and in-vivo 
effects were examined. The review article and the obtained results, which show reactivators´ 
composite mechanisms of action has been published in scientific journals and presented in the 









2 Review of literature 
 




Cholinesterases belong to a family of hydrolases and are able to split the ACh in the 
synaptic cleft to choline and acetic acid (Fig.1). These products are reused for the synthesis of 
new ACh. Two structurally and functionally very similar enzymes occur in a body. 
Acetylcholinesterase (AChE; EC 3.1.1.7) and butyrylcholinesterase (BuChE; EC 3.1.1.8). 
Both catalyze hydrolysis of ACh with similarly high efficiency but they differ in the 
distribution in the body and in the affinity to larger substrates. BuChE occur in the blood 
plasma, kidney and liver and is able to more effectively hydrolyze esters with larger moieties. 
Its role in the organism is still unclear but it is suggested that it degrades some esters, which 
arise from metabolism. Interestingly, mice lacking the AChE gene but having normal BuChE 
activity can survive more than one year, but are more sensitive to organophosphate (OP) 
poisoning. This suggests that BuChE may substitute at least in part for the lack of AChE 
activity [7]. Generally, BuChE also binds bulky ligands. AChE, that plays a key role in 
cholinergic neurotransmission, is mainly found in the central nervous systems, neuromuscular 
junctions, and the hematopoietic system of vertebrates [8]. Cholinesterase activity has been 
















Figure 1: Cleavage of ACh to choline and acetic acid 
 
 Both enzymes in vertebrates are encoded by one gene. Even though the primary 
structure differs interspecially, the structure of active sites essential for catalysis of ACh 
differs very little. Catalytic subunits of both cholinesterases consist of a single 500 to 600- 
amino acid-long peptide. The site of catalysis is buried 20 Å deep into the center of the 
globular catalytic subunit [8]. The key unit at the active site of the human enzyme, which is 
responsible for the enzymatic reaction, is the catalytic triad and consists of 3 aminoacids 
(Ser200, His440, Glu327) [13]. The oxyanion hole (Gly18, Gly119, Ala201), that is localised 
in the vicinity of the triad, stabilizes carbonyl oxygen of ACh during hydrolysis [14]. Binding 
sites are the acyl pocket, the choline binding site, and the peripheral site. The acyl pocket and 
the choline binding site are located next to the active serine, controlling the size of ligands. 
The peripheral site (Tyr70, Tyr121, Trp279) is located at the rim of the gorge, approximately 
14 Å from the active serine. It binds cationic and aromatic inhibitors that are too large to enter 




2.1.2 Cholinergic receptors 
 
There are two types of receptors for ACh, muscarinic and nicotinic. While nicotinic 
receptors occur at the neuromuscular end-plate and in the autonomic ganglion, muscarinic 
receptors occur on smooth muscle and glandular cells as well as on nerve terminals [15, 16]. 
 
2.1.2.1 Muscarinic receptors 
 
Five known subtypes (M1-M5) of the muscarinic acetylcholine receptors (mAChRs) 
have been distinguished. They belong to the G-protein coupled receptor (GPCR) superfamily. 
The M1, M3 and M5 subtypes are coupled to the activation of phospolipase C through G-
protein leading to the activation of inositolphosphate cascade of second messengers. They are 
extensively expressed on postsynaptic terminals where they facilitate fast synaptic 
transmission and metabotropic functions [17]. The muscarinic M2 and M4 subtypes may be 
regarded as inhibitory since they may reduce cAMP formation and prolong potassium channel 
opening. They also act as inhibitory autoreceptors on presynaptic terminals, thus inhibiting 
the neurotransmitter release from presynaptic terminal. On the other hand, M1 subtype 
localized presynaptically may enhance ACh release from the nerves [18]. M1 mAChRs are 
widely expressed in the brain, but significant levels have also been reported in salivary glands 
and sympathetic ganglia [19, 20]. M3 mAChRs are found extensively in smooth muscles of 
the GIT and urinary tract, where they play a major role in contraction and in secretion of 
exocrine glands [16]. M5 mAChRs has been identified in recent years in various peripheral 
and cerebral blood vessels [20, 21]. M2 mAChRs are abundantly expressed in the heart, 
smooth muscle organs and in the caudal formation of the brain. M4 mAChRs are widely 
expressed in lungs, brain and in lower concentration in the salivary glands and ileum. The 
study of mAChRs is complicated due to the low degree of selectivity of agonists and 
antagonists. Absolutely selective compound for individual subtype does not exist [22].  
 
2.1.2.2 Nicotinic receptors 
 
Nicotinic receptors belong to the ion-channel coupled receptor family and are 
responsible for fast excitatory synaptic transmission at autonomic ganglia, neuromuscular 
junctions and at various locations in the CNS. Two major classes of nicotinic acetylcholine 
receptors (nAChRs) have been distinguished. Neuronal-type and muscle-type. The classes 
differ in molecular structure and pharmacological properties. Furthermore, each class can be 
divided into subclasses, that also exert pharmacological heterogeneity too e.g. different 
ligands exist. The neuronal subtype forms a heterogeneous family of ion channels, which are 
differently expressed in many regions of the CNS and peripheral nervous system. These 
different receptor subtypes, which have characteristic pharmacological and biophysical 
properties, have a pentameric structure consisting of the homomeric or heteromeric 
combination of 12 different subunits (α2–α10, β2–β4) [23]. The muscle-type receptors 
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mediate ion permeation at the neuro-muscular endplate. They are pentameric complexes, 
consisting of four distinct protein subunits (α1β1γδ) in the ratio of 2α:1β:1γ:1δ [24]. An 
epsilon subunit is substituted for the gamma subunit during development, altering the 
functional response of the receptor [25]. It has been also reported that nAChRs are present in 
a number of non-neuronal cells, where they play a significant functional role [23].  
 
 
2.2 Organophoshorus poisoning 
2.2.1 Inhibitors of AChE 
 
There are two main groups of inhibitors – reversible and irreversible. Reversible 
inhibitors rapidly form non-covalent complexes with AChE at the active center or at the 
peripheral site or they may bind to both of them at the same time. These inhibitors can be 
drugs (e.g. donepezil, tacrine, physostigmine), oxime reactivators (HI-6, obidoxime) or ACh 
itself. On the other hand, irreversible inhibitors form a covalent chemical bond with the 
hydroxyl group of serine at the active site of the enzyme. Organophosphates (OP) and 




OPs represent an extremely toxic group of compounds. Members of this group can be 
both nerve agents (e.g., sarin, tabun, soman, cyclosarin, and VX) (Fig. 2) and pesticides (e.g. 
parathion, paraoxon, chlorpyrifos, malathion). These compounds inhibit AChE via its 
phosphorylation or phosphonylation at the serine hydroxyl group at its active site. The 
inhibition of the enzyme then manifests as a cholinergic syndrome. Clinical effects of 
excessive ACh stimulation depend on their localization and the type of receptor that is 
affected. Peripheral and central nervous symptoms exerted by muscarinic and nicotinic 
receptors are characteristic for organophosphate poisoning [1]. When an individual is exposed 
to a nerve agent, dose-dependent symptoms can be observed. These symptoms vary according 
to which receptor was affected. Typical muscarinic symptoms are dyspnoe, nausea, vomitus, 
diarrhea, miosis, hyperactivity of urinary bladder and hypersecrection of glands. Nicotinic 
symptoms manifests as weakness, tremor, tetanus and paralysis of striated muscles. Headache, 
slurred speech, hallucinations, anxiety and fuzziness are results of central poisoning. Paralysis 
of respiratory muscles and respiratory center in the brain is considered to be the major toxic 
effect that may lead to death [4]. 
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Figure 2: Structures of OP nerve agents  
 
The OP inhibition of AChE, and in particular the efficacy of its treatment, is 
complicated by the so called “aging” (Fig. 3). Aging is a loss of an additional alkyl substituent 
group from the enzyme-inhibitor complex [26]. This dealkylation depends on the length of 
contact with inhibitor and on the structure of inhibitor [1]. Primary alkyls ages slowly, while 
secondary, especially branched alkyls undergo aging rapidly (e.g., soman). In other words, 
aging is a period of time within it is possible to reactivate the inhibited AChE. Aging of nerve 
agents such as soman is very fast and occurs in a few minutes, whereas aging of pesticides 
such as paraoxon or ethyl-dichlorvos can take days [27]. 
 













Figure 3: Aging of the inhibited enzyme 
 
2.2.2 Therapy of OP poisoning 
 
The strategy for therapy of poisoning has to be considered out of its relation to the 
time point of exposure. At an early stage, before exposure, the strategy could be considered as 




Prophylaxis is an option when an exposure to OP is expected. Various approaches are 
available [3]. Carbamates (pyridostigmine, physostigmine, aminostigmine) are reversible 
inhibitors of AChE with higher affinity than Ops, i.e. AChE can not be inhibited irreversibly. 
After spontaneous recovery normal AChE serves as the enzyme source. Carbamates can be 
administered together with cholinolytics, as benactyzine and trihexyphenidyle (PANPAL), 
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which reduce adverse effect of pyridostigmine on the periphery and reduce toxic effect of OP 
in CNS. Enzymes capable to split OP compound are another possibility. Such an enzyme is 
paraoxonase [28], which is still under development. Thirdly, scavangers are able to bind 
molecules of OP and by that protect AChE from the binding of the OPs. These compounds are 
exogenously administered. Artificially developed AChE and BuChE seems to be very 
effective as the prophylactic agents in this way [3]. Furthermore, the current standard oxime 
reactivators currently used in the post-exposure treatment exert prophylactic effects too. 
However, other routes than standard administration is necessary to ensure a prolonged 
duration of the effect. Transdermal administration of one of the most effective reactivator (HI-




The treatment is ensured by two functionally different groups of drugs. (1) 
Reactivators of AChE - oximes - are able to restore the physiological function of inhibited 
AChE. (2) Anticholinergics, like atropine, are able to antagonize the effects of excessive ACh 
by a blockade of muscarinic receptors. Anticholinergics and reactivators can be administered 
together because of their synergistic effect. In addition, diazepam or other benzodiazepines 
can be used as anticonvulsants [4].  
Atropine is still a major anticholinergic agent. However, it blocks muscarinic receptors 
mainly in the periphery, and it lacks nicotinic antagonism [29]. The advantage of atropine is a 
high tolerance at high, life-saving doses (more than 100 mg during 24 hours). For better BBB 



















































Figure 4: Commonly used oxime reactivators 
 
Reactivators of AChE (Fig. 4) contain oxime moiety attached to a quaternary nitrogen 
pyridinium ring and are by this able to reactivate AChE inhibited by OP agents. The 
quaternary nitrogen is attracted by the anionic site of AChE and the reactivation occurs 















   
Figure 5:  Reactivation of inhibited AChE by oxime. AChE inhibited by organophosphorus 
compound being nucleophilicly attacked by an oxime moiety of pyridinium reactivator. AChE 
structure is restored and the reactivator binds the organophosphate. 
  
The antidotal treatment by oximes is still limited due to the following reasons: 1. no 
versatile antidote capable to effectively restore activity of AChE inhibited by random 
organophosphates has been developed yet. 2. Oxime reactivators are efficient only when 
administered before the “aging”. HI-6 and obidoxime are the most commonly used oxime 
reactivators in the treatment of organophosphorus poisoning. Moreover, HI-6 is considered as 
the most effective and is a broad-spectrum antidote against soman, sarin and VX [4], but it is 
less effective against tabun [31]. On the other hand, obidoxime is used against poisoning by 
tabun as well as by pesticides. Trimedoxime can be used for tabun poisoning as well. 
Pralidoxime can handle poisoning by sarin and VX, but in other cases is not as effective as H 
oximes (HI-6, Hlö-7) [4]. Some sources consider pralidoxime as obsolete or at least 
controversial [32, 33]. Methoxime, which is commonly used in the USA, exhibits lower 
reactivation potency against soman and tabun, but exerts good efficacy against sarin and VX 
[4].  
The high therapeutic potency of HI-6, besides its reactivating potency, might also be 
due to other antidotal mechanisms such as direct antimuscarinic and antinicotinic actions, 
restoration of neuromuscular transmission, retardation of the formation of the aged inhibitor-
enzyme complex and inhibition of ACh release [34, 35].  
In addition to these “standard reactivators” some new promising compounds have 
been developed such as K027 and K203 (Fig. 6). K027 is a very effective reactivator of 
methylparaoxone-inhibited AChE [36-38]. Moreover, since it has a lower toxicity than 
obidoxime, it may lead to a replacement of obidoxime as the preferred antidote in the 
treatment of poisoning by pesticides. K203 is also an effective compound in cases of tabun-
inhibited AChE. The results from in-vitro as well as in-vivo examinations in rats indicate that 
















2.3 Interaction of oximes with muscarinic and nicotinic receptors 
 
It is evident, that the major mechanism of action of the antidotes is the reactivation of 
inhibited AChE. However, other mechanisms may be involved. The data derived from tabun 
or soman lethally intoxicated primates suggest that, due to the lack or low reactivation 
potency of some agents, other mechanisms, not related to reactivation, may lead to survival 
via recovery of neuronal transmission in the respiratory centers and in the diaphragm [40, 41]. 
Similar life-saving results were obtained in a rat model, where rapidly aging crotylsarin was 
used and administration of HI-6 caused the recovery of neuronal transmission [42].  
The exact pharmacological effects of oximes are still an open question. Oximes 
probably play a role at various levels of the cholinergic transmission, from the synthesis and 
release of Ach trough the interaction with pre- and post-synaptic receptors to the re-uptake of 
transmitters. Clement reported that oxime HS-6 inhibits the synthesis of ACh, the release of 
ACh and the re-uptake of choline in the chicken [43]. The release of ACh from presynaptic 
fiber can be modulated in both ways suggesting an interaction with presynaptic muscarinic 
[44] and/or nicotinic receptors [45] or via the interaction with the HACU transporter system 
(High Affinity Choline Uptake), which is a key-regulatory system in the synthesis of ACh 
[46]. In the latter case, the interaction with presynaptic muscarinic receptors is also suggested 
[47]. While a decrease in release have been reported in the rat brain [48], an increase has been 
reported in the rat striated muscle [49].  
 
The interaction of reactivators with postsynaptic receptors has been described by many 
authors. In the treatment, some oximes have been reported in primates to be effective against 
soman poisoning even after aging  [41] and some compounds are effective even when the 
compounds lack the oxime moiety [50, 51].  
The effect on nicotinic receptors at the neuromuscular junctions was examined via the 
phrenic nerve-diaphragm model. HI-6 has been reported to counteract the failure of 
neuromuscular transmission caused by crotylsarin. Since HI-6 had similar effect as pure 
cholinergic receptor antagonists (gallamine, mecamylamine), which are not involved in AChE 
reactivation, nicotinic antagonism of this compound has been suggested. Furthermore, HI-6 
has been shown to be able to counteract crotylsarin-induced excessive release of 
3
H-ACh 
from an isolated endplate [5]. Tattersall examined the action of oximes on the nicotinic ion 
channel in the mice muscle endplate by using of single-channel recording. He suggested that 
pharmacological action against soman blockade in-vitro is due to the channel blocking 
activity of HI-6, obidoxime, trimedoxime and similar compounds [52]. Ganglion blocking 
properties has been suggested also by Lundy et al., since some oximes may cause a reduction 
of the blood pressure in cats [53]. Nicotinic receptors (and muscarinic as well) in the rat brain 
have been said to be blocked by some bispyridinium compounds as judged by displacement 
examinations with tritiated QNB [54]. However, single channel studies have revealed that HI-
6 and pralidoxime increases the opening probability of nicotinic receptors that are activated 
by ACh [55].  
Concerning the blocking properties of the muscarinic receptors, binding studies of 
some H-oximes has been performed on mice smooth muscle tissue. Their inhibitory constants 
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are in the micromole range. However, as observed also at nicotinic receptors, it does not 
correlate with the efficacy against soman in-vivo [56]. Functional muscarinic antagonism has 
been observed at guinea pig as well [57]. The mechanism of binding to the muscarinic 
receptors is still not fully understood, but an allosteric manner has been suggested [58, 59]. 
Obidoxime has been reported to be a competitive ligand at the common allosteric site [60, 
61]. Moreover, in-vitro testing proved the oxime HGG-12 (and the analog HGG-42) to also be 
allosteric inhibitors [44]. Ellis and Seidenberg investigated the effect of obidoxime and other 
ligands (tacrine, gallamine) on rat cardiac muscarinic receptors and concluded that obidoxime 
is a weak allosteric inhibitor [60]. Cholinergic activity of oxime HGG-12 has been described 
as competitive antagonism without intrinsic activity at porcine atrial muscarinic ACh 
receptors. The stimulatory action on muscarinic receptors, which has been described by 
several authors, is therefore suggested to be due to partial inhibition of AChE by the oxime 
rather than to direct agonism at muscarinic ACh receptors [62].  
Anti-AChE activity of bispyridinium compounds has also been observed when 
measured physiologically in the guinea pig ileum [63] or spectrofotometrically in-vitro [64] 
and therefore indirect stimulatory effects can be concluded to occur at a cholinergic system as 
well.  
Thus, in can be concluded, that pharmacological effects of oximes are complex and 
not yet well defined. There is a hypothesis that oxime reactivators used in the treatment of OP 
poisoning exert both antimuscarinic and anticotinic properties. However some questions still 
need to be answered.  
 
1. Are the non-esterase inhibitory properties of oximes significant for the treatment of 
OP poisoning and by which mechanisms do they exert the effects? 
2. Are there differences among reactivators in anticholinergic efficacy?  
3. Why is there a difference between in-vitro and in-vivo effects of the oximes? 
 
This thesis tries to answer these questions. Therefore, two commonly used reactivators (HI-6, 
Obidoxime) and two newly synthesized promising compounds (K027 and K203) have been 
chosen in order to investigate their properties at different levels in the cholinergic 
















It is obvious that different approaches of investigation require different techniques. 
Methods that were used are described in detail in individual publications (appendix 10.1-
10.8). Here is just a short summary, presented in a muscarinic and a nicotinic section, in order 
to explain the principle of applied procedures. 
 
3.1 Muscarinic receptors 
 
3.1.1 Binding study (10.7) 
 
The affinity of reactivators has been measured. Radiolabeled ligand of muscarinic 
receptors N-methylscopolamine (NMS) was displaced by the tested compound. Higher 
affinity of tested compound results in larger decrease of radioactivity, which was measured in 
a scintillation counter. As source of muscarinic receptors, rat brain homogenates were used.  
 
3.1.2  GPCR activation assay (10.7) 
 
In order to get functional correlates to the binding examinations, the activation of G-
protein coupled receptor (M2) was measured. A commercial kit based on measuring β-arrestin 
recruitment was used to reveal the transduction of the signal through the muscarinic receptors 
into the second messengers. Affinity of the tested ligands and its intrinsic activity were 
evaluated. Currently, the decrease in activation caused by oxotremorine-M (muscarinic 
agonist) was studied for various oximes (muscarinic antagonists).  
 
3.1.3 Functional study in-vitro 
 
Further functional correlates were searched for in in-vitro studies using tissue bath 
where isolated organs were placed after dissection from rats. The models enable studies in a 
more complex model. The tissue bath simulates a physiological environment where the whole 
organ can undergo examinations. Rat urinary bladders (M3 receptor occurrence, 10.1, 10.6) 
and atria (M2, 10.6) were used. By employing the muscarinic agonist methacholine, the 
receptors were stimulated to provoke smooth muscle contraction (bladder) or decrease in the 
heart frequency (atria). The responses were recorded in the presence and in the absence of 
tested reactivators. Interaction of reactivator and the AChE sometimes occurred, but since 






3.1.4 Functional study in-vivo (10.6) 
 
In order to get indications for the clinical significance of different mechanisms, in-vivo 
studies were performed. The in-vivo examinations were performed on anesthetized rats. All 
drugs were administered via v. femoralis and the blood pressure and BPM were monitored via 
catheter introduced into the a. femoralis. The vagal nerve was stimulated via platinum 
electrode, which resulted in a drop of the heart frequency, due to the release of ACh from the 
nerve terminal and its effect on atrial muscarinic M2 receptors. The heart frequencies 
recorded in the presence and in the absence of tested reactivators and their effect were 
observed. The interaction with AChE may occur since endogenous ACh is broken down by 
AChE, which can be inhibited by reactivator.  
 
3.2 Nicotinic receptors (10.8) 
 
3.2.1 Patch clamp (in-vitro) 
 
Nicotinic receptors are members of ion-channel family of receptors. The activated 
receptor is characterized by the current of ions (Na
+
) through it. This current manifests as a 
change in amperage and the change can be measured via patch clamp technique. This method 
requires some carrier of the nicotinic receptor – currently TE671 cell line was used, which 
expresses a human embryonic muscle nAChRs. First, cells were stimulated by ACh to obtain 
a basal activation. Then ACh was administered together with a reactivator and the currents 
were compared.   
 
3.2.2 Functional study in-vivo 
 
The in-vivo functional studies were performed by measuring effects on nAChRs 
localized in the neuro-muscular endplate. By electrical stimulation of the innervation, muscle 
contractions were induced. The examination was performed on anesthetized rats. All the 
drugs were administered via v. femoralis and the muscle twitches were recorded via a thread 
fasten to the m. tibialis and to a recording device. The twitches were evoked by a platinum 
electrode placed to the nervus sciaticus. The twitches of m. tibialis ant. were recorded in the 








3.3 Additional studies 
 
3.3.1 Interaction of oximes with AChE (10.1, 10.2, 10.3, 10.4, 10.6) 
 
Oxime reactivators are potential AChE inhibitors, and therefore the effect of the 
oximes on the AChE needs to be quantified when the direct interactions at the receptor level 
are to be evaluated. The AChE inhibition may influence the receptor interaction indirectly. 
Often the inhibition of receptors and the inhibition of AChE are two contradictory processes. 
In order to assess the AChE interaction, the classical spectrophotometrical Ellman´s method 
based on the colored reaction of AChE with acetylthiocholine (substrate) and chromogen was 
applied. 
 
3.3.2 Interaction of oximes with HACU (10.4) 
 
The investigation of oximes and HACU has been published on just one reactivator 
(K112) in order to describe their complex mechanism of action. HACU system is a key 
regulatory step in the synthesis of ACh and is responsible for the transport of choline to the 
presynaptic cleft, where choline is used for new syntesis of ACh. In other words, inhibition of 
HACU leads to shortage of ACh in the synapsis, which may also be important in OP 






















4 Comment to the results 
 
The aim of the thesis is to describe the interaction of oxime reactivators on the 
muscarinic and nicotinic receptors. First of all, the principle statement should be that, there 
exists an interaction before studying any mechanism in detail. This first step is fairly easily 
performed. However, to describe any interaction in detail is a little bit more complicated, 
since oxime reactivators exert very complexed mechanisms of action and have influence on 
various levels of cholinergic system. According to the literature and according to our 
observations, it may be concluded that oxime reactivators have antagonistic effect on both 
muscarinic and nicotinic receptors. However, cholinomimetic actions of these drugs can not 
be definitely excluded. There exist some evidences for the latter statement, which, however, 
depend on the method applied. In order to elucidate the mechanism of action, two standard 
reactivators (HI-6, Obidoxime) and two-newly synthesized drugs (K027, K203) were tested.  
The binding study revealed the affinity of oximes to the the mAChRs. The affinity 
increases in following order HI-6<K203≈K027<Obidoxime. However, even the one with the 
highest affinity, obidoxime, could not reach the affinity of atropine which was 3-fold higher 
(10.7). This finding is in agreement with most other similar studies [56].  
The binding to the mAChRs receptors is a prerequisite for the transduction of the 
signal trough the receptor, which, in the case of G-protein coupled receptors leads to the 
activation of the G-protein. In the GPCR activation based study (10.7), the oximes blocked 
the activation induced by oxotremorine (muscarinic agonist; control). No intrinsic activity of 
the oximes was observed and the blocking properties of the signal transduction increased in 
the following order: HI-6<K027<K203 ≈Obidoxime. This roughly corresponds to the binding 
affinities at least in that HI-6 has the lowest and obidoxime has the largest effect (10.7).   
 
The in-vitro contraction study on the isolated rat urinary bladder showed antagonistic 
effect on M3 mAChRs (10.1, 10.4. 10.6). However, this effect was only obvious at higher 
concentrations of oximes. At lower concentrations, an opposite effect was observed (increase 
in contraction). This is probably due to an inhibition of AChE caused by the reactivators. In 
the atrial preparation, only the antagonistic effect on M2 mAChRs was observed (increase in 
heart frequency) (10.6., 10.7). An explanation to this fact seems not far to seek. For 
stimulation of M2 mAChRs methacholine (agonist), which is not broken down by AChE, was 
used i.e. potential inhibition of AChE did not result in the accumulation of agonist in the 
synapsis. However, methacholine was used to stimulate the bladders as well and here the 
effect on AChE was observed. This could be due to the fact that in the bladder, there is a 
pronounced non-neuronal production and a release of acetylcholine from the urothelium 
occurs. The mechanisms that induce the release is largely unknown, but is most likely to be 
induced by shear stress, i.e. stretch of the urothelium may be caused by the methacholine-
evoked contraction [65]. Also, the activation of urothelial muscarinic receptors may 
contribute to the release. It means that the observed effect is due to the AChE inhibition and 
its influence on ACh´s break down, not that one of methacholine. Interestingly, the 
comparison of individual agents´ efficacy showed a high potency of HI-6 (and possibly 
obidoxime), which does not correlate with the affinity studies, where HI-6 showed the lowest 
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affinity to mAChRs. An explanation could be found in the interaction with presynaptic 
receptors, the HACU system or in another mechanism that influence the release of 
endogenous ACh.  
 
The in-vivo muscarinic studies of the heart frequency in anesthetized rat, has been 
published only for obidoxime and K112 (10.6, 10.4), however, qualitatively similar effects 
could be expected from other reactivators as well. Once again, both the effect on the AChE 
and that on the M2 mAChRs appeared. Interestingly, it occurred the other way around than in 
the bladder, i.e. at lower doses the M2 mAChRs was affected and at higher doses the AChE. 
Tentatively, it indicates the in-vivo affinity of the oximes: M2>AChE>M3. The effect on 
AChE could possibly be observed since the stimulation of vagal nerve leads to the release of 
endogenous ACh, which is not broken down by inhibited AChE. In the case of K112 (10.4) a 
clear dose-dependent antimuscarinic effect was observed. However, no effect was observed 
on AChE. It might be explained by different experimental conditions and higher affinity of 
K112 to the mAChRs (data not shown); at 5 Hz stimulation instead of 10Hz, less 
acetylcholine is released and by that, it is harder to overcome the K112 antimuscarinic 
blockade at the lower frequency. In other words, the enzyme blockade does not overcome the 
muscarinic blockade (which might occur at larger doses than those examined). Other 
reactivators have also been examined and (unpublished) results show a similar progress like 
that in the case of obidoxime, supporting the idea of a dual effect of the reactivators. It must 
be said, that in case of the trimedoxime´s effect on bladder (10.3), this dual effect was not 
observed. This could be explained by comparable effects on AChE and on the muscarinic 
receptors, which counteraction leveled out the result seen in the composite response. The 
same type of in-vitro experiments but using atropine instead, showed, as could be expected, 
only the antimuscarinic action. However, a notably higher potency was observed. 
The interaction of oximes with AChE was quantified by using the 
spectrophotometrical Ellman´s method (10.1-10.7). The potency to inhibit AChE occurred in 
the following order: HI-6>K027>K203>Obidoxime. Interestingly, this was in fact vice versa 
than the affinity of the same oximes to mAChRs. Tentatively, it may be concluded that the 
stronger AChE inhibitor, the less potent binding antagonist. On the other hand, we must take 
into consideration, that it is only relatively few observations in each group investigated in this 
way. 
 
In-vivo observations on nicotinic effects (10.8) showed clearcut dose-dependent 
reductions in nerve-evoked twitches, which indicate a blockade of nicotinic receptors at the 
neuromuscular endplate. These effects could be observed at both 1 Hz and 5 Hz. At 5 Hz 
stimulation, smaller inhibitory effects appeared, probably due to a larger availability of ACh 
at this frequency. Even though no statistical significance appeared, still clear dose-dependent 
effect occurred. Concerning the individual compounds, only small differences in potency 
appeared. If any difference in potency occurred between the various oximes, it was somewhat 
less for K027. It should stressed that spontaneous fading of twitches may occur during a 
repetitive stimulation, probably due to changed sensitivity of the perceptual receptors [66]. 
However, a decrease by 23% was reported after delivery of 3000 stimuli. In our study, only 
about 1000 stimuli were delivered and the reduction observed was up to 50 %. Nevertheless, 
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the current results indicate a direct antagonistic effect of oxime reativators on the nAChRs. To 
the best of my knowledge, this is the first in-vivo report that oximes inhibit nicotinic 
receptors.  
Interestingly, in the case of neuromuscular transmission, no effect on AChE was 
noticed, as in case of the muscarinic in-vivo examination. It must be considered that the 
physiological processes at central and neuromuscular synapsis differ. The AChE due to a 
posttranslational processes occur in different molecular forms, which has the same activity but 
differ in the affinity to AChE inhibitors [67]. Moreover, the approximate maximum response 
to autonomic stimulation occurs in the range 15 – 40 Hz. The corresponding interval to 
maximum responses to motoric stimulation occurs above 40 Hz (40 – 70 Hz or even higher). 
The quantal theory of ACh release approximates the release of 1000 molecules of ACh per 
quantum in the CNS and 6000-10000 per quantum in the neuromuscular junction [68]. In the 
current experiments, 10 Hz was applied for the vagal stimulation and only 1 and 5 Hz for 
neuromuscular stimulation. One explanation is that oximes have a more pronounced 
antagonistic effect on the nAChRs than on the mAChRs in relation to the AChEi effect. On 
the other hand, it has been shown that H-oxime has lower affinity to the nAChRs than on the 
mAChRs [56]. However, these two situations are somewhat incomparable and various 
theories are at hand concerning the effect on AChE, but the antagonistic effects on nAChRs 
and on the mAChRs are doubtless. 
The antagonistic effect on the nAChRs has been also confirmed by using in-vitro 
patch-clamp technique (10.8). The results showed antagonistic activity of all tested 
compounds on the muscle type of nAChRs (IC50 in the range of hundreds of micromoles). 
Once again, apparent lower potency of K027 has been observed. Comparing this efficacy with 
in-vitro muscarinic examinations, the potency on the mAChRs is approximately by one fold 
higher. This is very well in agreement with previous observations [56]. 
 
In order to describe complex mechanisms of action of the reactivators, the interaction 
of oximes with the HACU transport system and their effect on membrane fluidity was 
investigated. This system is a key regulatory step (rate-limiting) in the synthesis of new ACh. 
Standard oxime reactivators (not published) and K112 (published, 10.4) were exerted to this 
system. In general, the results showed that oxime reactivators are able to interact with this 
system at low (K112, trimedoxime) or high concentrations (HI-6, obidoxime). In the first 
group the direct inhibitory effect on (3H)-choline reuptake was observed at low 
concentrations (10 µM). However, in the second group, a higher concentration (50µM) 
influenced the transport of (3H)-hemicholinium-3 (competitive, reversible, non-permeant 
ligand of the transport system). The inhibition of HACU is probably due to a direct interaction 
with the hemicholinium-sensitive carrier, since the effect on the anisotropy of the membrane 
is less likely to occur under the present conditions. Furthermore, inhibition was connected 
with changes in the affinity rather than with changes in the number of binding sites. These 
results exhibit strong evidence for other mechanisms being involved in the release of ACh. 
Furthermore, oxime reactivators are likely to influence them as well. 
 
It is well known that results from in-vitro examinations do not always correlate with 
in-vivo findings [52, 56]. E.g. HI-6 can handle an in-vivo  tabun poisoning [69], whereas it in-
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vitro shows only a minute reactivation potency [70]. In our study, we observed a similar 
situation. HI-6, being less effective in the in-vitro testing, showed considerably higher 
potency when examined in the whole (isolated) organ or in-vivo. This supports the hypothesis 
that oxime reactivators dispose very complex mechanisms of action and in case of HI-6 it may 
explain its versatility and broad spectrum usage. 
 
 
In conclusion, by using various in-vitro and in-vivo techniques, previous hypotheses 
are confirmed. Also, the thesis reveals new mechanisms in the antagonistic effect of oxime 
reactivators on the muscarinic and nicotinic receptors. This effect is likely to be of great 
significance in the treatment of OP poisoning, where the relative ACh excess can be 
counteracted by the blocking properties of oximes on cholinergic receptors. The comparison 
of the in-vitro data, showed the oximes to exert higher efficacy on the muscarinic than on the 
AChE. However, this effect seemed to be subtype specific since the antagonistic M3 effect 
was lower (M2>AChE>M3). Also, and importantly, the antagonistic muscarinic effect was 
larger than that on nicotinic receptors. Furthermore, in comparison with other drug used in the 
treatment, the classical antidote atropine showed a much higher muscarinic antagonism. 
Despite all of this, it is supposed that non-reactivation properties of oxime reactivators play a 
significant role in the treatment of OP poisoning. In the current publications, a dual effect on 
cholinergic receptors and on AChE at the same time is shown. This property is of course not 
in favor in the antidotal treatment. It should be stressed that this effect on AChE has not been 
observed in the nicotinic transmission. Since overstimulation of nicotinic is considered to be 
the cause of death in the OP poisoning, clear antinicotinic action is of advantage.  To the best 
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8 Summary in English 
 
Currently, organophosphorus (OP) poisoning is a threat particularly in war conflicts in 
connection with terrorism or a poisoning caused by OP pesticides in agriculture. The 
poisoning is caused by inhibition of the enzyme acetylcholinesterase (AChE), which, under 
physiological conditions, cleaves acetylcholine (ACh) and regulates the transmission of nerve 
signals. The inhibition of AChE leads to excessive stimulation of cholinergic receptors and 
clinically it manifests as so-called cholinergic syndrome. According to the structures affected, 
symptoms are divided into nicotinic, muscarinic and central. Organophosphates are lethal 
compounds, when death is caused by suffocation. Current treatment is mainly based on the 
application of anticholinergics (atropine) and /or on the application of AChE oxime 
reactivators (HI-6, obidoxime, pralidoxime etc.) Atropine inhibits excessive neural 
transmission by blocking muscarinic receptors. However, it is only symptomatic cure not 
causal. Whereas oximes, which represent a causal therapy, are able to unbind an OP 
compound from the AChE and restore its splitting function. 
Using reactivators has two major drawbacks; there is no universal reactivator against all types 
of OP compounds (soman, sarin, paraoxon etc.) and reactivation is possible only within a 
certain time after the exposure ("aging"). Based on these limiting factors, it is essential to 
keep searching for a universal oxime or apply different therapeutic approaches. 
One possible approach is a deeper examination of the reactivators´ mechanism of action since 
they have a very complex effect on the whole cholinergic system. In particular, their ability to 
influence the nervous signal transmission at the receptor level.  
The aim of this dissertation thesis is to study the cholinergic effects of oxime 
reactivators (especially their effect on the muscarinic and nicotinic receptors) and the 
significance of non-reactivating properties in the treatment of organophosphate poisoning.  
We selected two commonly used reactivators (HI-6 and obidoxime) and 2 newly synthesized 
reactivators (K027 and K203) for this purpose. These 4 compounds were studied by using 
various techniques involving in-vitro and in-vivo experiments. Specifically, reactivators’ 
affinity for muscarinic receptors, effect on signal transduction, functional experiments on the 
tissue samples (isolated heart atrium, urinary bladder in the organ bath) and on the whole 
body (impact on rat heart rate). Nicotinic effects were also studied using in-vitro (cell patch-
clamp) and in-vivo (rat neuromuscular effects) methods. Other experiments were performed in 
order to describe a direct effect on AChE or on the choline re-uptake as the other cholinergic 
structures that may be affected by reactivators.  
The experimental data showed that AChE reactivators have a very complex 
mechanism of action. They exert the inhibitory effect on AChE with the efficacy at least 3-
fold lower than the commonly used central inhibitors of AChE. Furthermore, they display 
inhibitory effect on the high-affinity choline uptake transporter (HACU), which is a key-
regulatory step in the ACh synthesis de novo. In-vitro and in-vivo experiments 
comprehensively proved inhibitory effects of studied oximes on nicotinic receptors. Although, 
the IC50 values were in the hundreds of micromoles, even a weak inhibition may speak in 
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favor of the treatment with reactivators. Moreover, atropine does not affect nicotinic receptors 
at all and unfortunately nicotinic symptoms are usually responsible for the death of a victim. 
Muscarinic antagonism has also been verified by both in-vitro and in-vivo experiments. 
Although, the mechanism of binding has not been satisfactorily explained a weak inhibition 
was observed (atropine in all experiments possesses at least 3-fold higher efficacy). However, 
even a weak inhibition may play an important role in the treatment of OP poisoning, in 
particular, in the case of “aging”.  
Focusing on individual reactivators- HI-6, obidoxime, and K203 usually demonstrated 
a higher inhibitory efficiency than K027. Surprisingly, HI-6, that exerted the lowest affinity 
for muscarinic receptors, showed notably higher efficiency in more complex systems (the 
tissue level, the whole organism level). This fact suggests other mechanisms, than performed 
in this study, may be involved (e.g. the effect on presynaptic receptor, synthesis or the release 
of ACh). Moreover, it also explains why HI-6 seems to be currently the most effective 
reactivator with the broadest spectrum of action.  
Review article and results from this dissertation thesis were published in Czech and 
international scientific journals (8x first-author papers, 7x IF). Furthermore, results were also 





























9  Shrnutí v českém jazyce 
 
Otrava organofosforovými (OF) sloučeninami je v současné době hrozbou zejména ve 
válečných konfliktech, ve spojení s terorismem či jako otravy způsobené v zemědělství OF 
pesticidy. Otrava je způsobena inhibicí enzymu acetylcholinesterázy (AChE), který za 
fyziologických podmínek štěpí acetylcholin (ACh) a reguluje tak přenos nervového signálu. 
V případě inhibice AChE dochází k nadměrné stimulaci cholinergních receptorů a klinicky se 
manifestuje jako tzv. cholinergní syndrom. Dle zasažených struktur se příznaky dělí na 
nikotinové, muskarinové či centrální. Jedná se o, dle dávky a doby expozice, letální látky, kdy 
smrt nastává udušením. Současné léčba sestává z aplikace anticholinergik (atropin), které 
blokují nadměrný nervový přenos inhibicí zejména muskarinových receptorů a/nebo  
z aplikace reaktivátorů AChE (HI-6, obidoxim, pralidoxim etc.), které jsou schopny vyvázat 
OF látku z vazby na AChE a tím obnovit její štěpící funci. Tato léčba je však limitována tím, 
že neexistuje univerzální reaktivátor, který je schopný vyvázat libovolnou nervově 
paralytickou látku (soman, sarin, paraoxon etc.), a tím, že reaktivace AChE je možná pouze 
do určité doby po expozici („aging“). Na základě těchto limitujících faktorů jsou vyvíjeny 
další universálnější reaktivátory či jsou vyhledávány jiné terapeutické přístupy. Tím spíš, že 
léčba atropinem je pouze léčba symptomatická nikoliv kauzální. 
Jedním z takových přístupů je hlubší prozkoumání mechanismu účinku reaktivátorů, 
protože se jedná o látky s velmi komplexním účinkem na celý cholinergní systém. Zejména 
jejich schopnost ovlivňovat přímo přenos signálu na receptorové úrovni (mechanismus 
podobný receptorové blokádě atropinem).  
Cílem této dizertační práce je prostudovat cholinergní účinky oximových reaktivátorů 
(zejména jejich účinek na muskarinové a nikotinové receptory) a posoudit přínos v terapii 
otrav organofosfáty u vlastností, které nemají nic společného s reaktivací AChE. 
K tomuto účelu byly vybrány 2 běžně používané reaktivátory (HI-6 a obidoxim) a 2 
nově syntetizované reaktivátory (K027 a K203). Tyto 4 látky byly studovány za využití 
různých technik v in-vitro i in-vivo experimentech. Konkrétně se jednalo o afinitu reaktivátorů 
k muskarinovým receptorům, jejich ovlivnění transdukce signálu, funkční experimenty jak na 
úrovni orgánů (izolované srdeční síně, močový mechýř v orgánové lázni) tak i na úrovni 
celého organismu (ovlivnění srdeční frekvence potkana). Nikotinické účinky byly studovány 
taktéž in-vitro (patch-clamp) i in-vivo (ovlivnění nervosvalového přenosu potkana). Další 
experimenty zabývající se přímým ovlivněním AChE reaktivátory či jejich vliv na re-uptake 
cholinu byly provedeny za cílem obsáhnout i další cholinergní struktury, které mohou být 
reaktivátory ovlivněny. 
Výsledky experimentů ukázaly, že reaktivátory AChE vykazují velice komplexní 
mechanismus účinku. Byl prokázán inhibiční účinek na AChE v řádech minimálně 1000x 
menších než běžně používané inhibitory AChE při léčbě Alzheimerovy demence. Dále pak 
byl prokázán inhibiční účinek na vysokoafinitní transport cholinu (HACU), který je 
rozhodující pro syntézu ACh de novo. Účinek na nikotinové receptory, byl z in-vitro i in-vivo 
experimentů shledán jako inhibiční. Ačkoliv se hodnoty IC50 pohybovaly v řádech stovek 
mikromolů, může tato slabá inhibice hovořit ve prospěch léčby reaktivátory tím spíš, že 
atropin nemá na nikotinové receptory prakticky žádný vliv. Muskarinový antagonismus byl 
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taktéž ověřen in-vitro i in-vivo pokusy. Ačkoliv mechanismus vazby nebyl uspokojivě 
vysvětlen, jedná se opět o slabé inhibitory (atropin ve všech experimentech byl minimálně 
1000x více účinný), avšak i tato slabá inhibice může hrát v léčbě otrav OF důležitou roli. 
Zejména v případě uplynutí doby, po kterou je AChE reaktivovatelná (po „agingu“).  
Pokud se jedná o jednotlivé reaktivátory, většinou HI-6, obidoxime a K203 
vykazovaly větší inhibiční efektivitu; K027 většinou menší. Překvapivě, látka HI-6 s nejnižší 
afinitou k muskarinovým receptorům vykazovala v komplexnějších systémech (orgán, 
organismus) vysokou účinnost, což nasvědčuje tomu, že i další než studované mechanismy 
mohou být zastoupeny (např. ovlivnění presynaptických receptorů, syntézy či uvolňovaní 
ACh). Zároveň dosažené výsledky vysvětlují to, proč se HI-6 v současné době jeví jako 
nejúčinnější reaktivátor s nejširším spektrem účinku.  
Rešerše a výsledky obsažené v této dizertační práci byly publikovány v českých i 
zahraničních odborných časopisech (8 prvoautorových prací, 7x s IF) a na českých i 
zahraničních konferencích v rámci přednášek či formou posterových sdělení.  
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